A central goal of The Academy of Breastfeeding Medicine is the development of clinical protocols for managing common medical problems that may impact breastfeeding success. These protocols serve only as guidelines for the care of breastfeeding mothers and infants and do not delineate an exclusive course of treatment or serve as standards of medical care. Variations in treatment may be appropriate according to the needs of an individual patient.
Get full access to this article
View all access options for this article.
References
1.
GjerdingenDK, YawnBP. Postpartum depression screening: Importance, methods, barriers, and recommendations for practice. J Am Board Fam Med, 2007; 20:280–288.
2.
ChaudronLH, SzilagyiPG, TangW, et al.Accuracy of depression screening tools for identifying postpartum depression among urban mothers. Pediatrics, 2010; 125:e609–e617.
3.
WisnerKL, PerelJM, PeindlKS, et al.Prevention of recurrent postpartum depression: A randomized clinical trial. J Clin Psychiatry, 2001; 62:82–86.
4.
MarcusSM.Depression during pregnancy: Rates, risks, and consequences—Motherisk Update 2008. Can J Clin Pharmacol, 2009; 16:e15–e22.
5.
OppoA, MauriM, RamacciottiD, et al.Risk factors for postpartum depression: The role of the Postpartum Depression Predictors Inventory-Revised (PDPI-R). Results from the Perinatal Depression-Research and Screening Unit (PNDReScU) study. Arch Womens Ment Health, 2009; 12:239–249.
6.
CutlerCB, LeganoLA, DreyerBP, et al.Screening for maternal depression in a low education population using a two item questionnaire. Arch Womens Ment Health, 2007; 10:277–283.
7.
EarlsMF; Committee on Psychosocial Aspects of Child and Family Health American Academy of Pediatrics. Incorporating recognition and management of perinatal and postpartum depression into pediatric practice. Pediatrics, 2010; 126:1032–1039.
8.
MishinaH, TakayamaJI. Screening for maternal depression in primary care pediatrics. Curr Opin Pediatr, 2009; 21:789–793.
9.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). American Psychiatric Publishing, Arlington, VA, 2013.
10.
SriramanNK.Postpartum depression: Why pediatricians should screen new moms. Cont Pediatr, 2012; 29:40–46.
11.
SharmaV.Treatment of postpartum psychosis: Challenges and opportunities. Curr Drug Saf, 2008; 3:76–81.
12.
ChaudronLH, PiesRW. The relationship between postpartum psychosis and bipolar disorder: A review. J Clin Psychiatry, 2003; 64:1284–1292.
13.
JonesI, CraddockN. Familiarity of the puerperal trigger in bipolar disorder: Results of a family study. Am J Psychiatry, 2001; 158:913–917.
14.
AbramowitzJS, Meltzer-BrodyS, LesermanJ, et al.Obsessional thoughts and compulsive behaviors in a sample of women with postpartum mood symptoms. Arch Womens Ment Health, 2010; 13:523–530.
15.
RussellEJ, FawcettJM, MazmanianD. Risk of obsessive-compulsive disorder in pregnant and postpartum women: A meta-analysis. J Clin Psychiatry, 2013; 74:377–385.
16.
National Institute for Health and Clinical Excellence. Postnatal Care: Routine Postnatal Care of Women and Their Babies (CG37). National Institute for Health and Clinical Excellence, London, 2006.
17.
Royal Australian College of General Practitioners. Guidelines for Preventive Activities in General Practice. Royal Australian College of General Practitioners, East Melbourne, Australia, 2012.
YawnBP, DietrichAJ, WollanP, et al.TRIPPD: A practice-based network effectiveness study of postpartum depression screening and management. Ann Fam Med, 2012; 10:320–329.
21.
Appendix A Task Force Ratings. Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force, 2nd ed. Available at www.ncbi.nlm.nih.gov/books/NBK15430/ (accessed May27, 2015).
22.
OlsonAL, KemperKJ, KelleherKJ, et al.Primary care pediatricians' roles and perceived responsibilities in the identification and management of maternal depression. Pediatrics, 2002; 110:1169–1176.
23.
ChaudronLH, SzilagyiPG, CampbellAT, et al.Legal and ethical considerations: Risks and benefits of postpartum depressions screening at well-child visits. Pediatrics, 2007; 119:123–128.
24.
U.S. Public Health Service. Report of the Surgeon General's Conference on Children's Mental Health: A National Action Agenda. U.S. Department of Health and Human Services, Washington, DC, 2000. Available at www.ncbi.nlm.nih.gov/books/NBK44233/ (accessed May27, 2015).
25.
Committee on the Psychosocial Aspects of Child and Family Health and Task Force on Mental Health. Policy statement—The future of pediatrics: Mental health competencies for pediatric primary care. Pediatrics, 2009; 124:410–421.
26.
MyersER, Aubuchon-EndsleyN, BastianLA, et al.Efficacy and Safety of Screening for Postpartum Depression. Comparative Effectiveness Reviews, No. 106. Agency for Healthcare Research and Quality, Rockville, MD, 2013. Available at www.ncbi.nlm.nih.gov/books/NBK137724/ (accessed May27, 2015).
27.
CoxJL, HoldenJM, SagovskyR.Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry, 1987; 150:782–786. Available at http://pesnc.org/wp-content/uploads/EPDS.pdf (accessed May27, 2015).
28.
HaganJFJr, ShawJS, DuncanP, eds. Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 3rd ed. American Academy of Pediatrics, Elk Grove Village, IL, 2008.
29.
SheederJ, KabirK, StaffordB. Screening for postpartum depression at well-child visits: Is once enough during the first 6 months of life?. Pediatrics, 2009; 123:e982–e988.
30.
FreemanMP, WrightR, WatchmanM, et al.Postpartum depression assessments at well-baby visits: Screening feasibility, prevalence, and risk factors. J Womens Health (Larchmt), 2005; 14:929–935.
31.
DennisCL.Can we identify mothers at risk for postpartum depression in the immediate postpartum period using the Edinburgh Postnatal Depression Scale?. J Affect Disord, 2004; 78:163–169.
32.
JardriR, PeltaJ, MaronM, et al.Predictive validation study of the Edinburgh Postnatal Depression Scale in the first week after delivery and risk analysis for postnatal depression. J Affect Disord, 2006; 93:169–176.
33.
WatkinsS, Meltzer-BrodyS, ZolnounD, StuebeA. Early breastfeeding experiences and postpartum depression. Obstet Gynecol, 2011; 118:214–221.
34.
TrapoliniT, McMahonCA, UngererJA. The effect of maternal depression and marital adjustment on young children's internalizing and externalizing behaviour problems. Child Care Health Dev, 2007; 33:794–803.
35.
MinkovitzCS, O'CampoPJ, ChenYH, et al.Associations between maternal and child health status and patterns of medical care use. Ambul Pediatr, 2002; 2:85–92.
36.
KavanaughM, HaltermanJS, MontesG, et al.Maternal depressive symptoms are adversely associated with prevention practice and parenting behaviors for preschool children. Ambul Pediatr, 2006; 6:32–37.
37.
StuebeAM, GrewenK, Meltzer-BrodyS. Association between maternal mood and oxytocin response to breastfeeding. J Womens Health (Larchmt), 2013; 22:352–361.
DennisCL, RossLE, GrigoriadisS. Psychosocial and psychological interventions for treating antenatal depression. Cochrane Database Syst Rev, 2007;(3):CD006309.
40.
BrandonAR, FreemanMP. When she says “no” to medication: Psychotherapy for antepartum depression. Curr Psychiatry Rep, 2011; 13:459–466.
41.
CuijpersP, BrannmarkJG, van StratenA. Psychological treatment of postpartum depression: A meta-analysis. J Clin Psychol, 2008; 64:103–118.
42.
O'HaraMW, SchlechteJA, LewisDA, et al.Prospective study of postpartum blues. Biologic and psychosocial factors. Arch Gen Psychiatry, 1991; 48:801–806.
43.
DekkerJJ, KoelenJA, VanHL, et al.Speed of action: The relative efficacy of short psychodynamic supportive psychotherapy and pharmacotherapy in the first 8 weeks of a treatment algorithm for depression. J Affect Disord, 2008; 109:183–188.
44.
O'HaraMW, StuartS, GormanLL, et al.Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry, 2000; 57:1039–1045.
45.
BrandonAR, CeccottiN, HynanLS, et al.Proof of concept: Partner-assisted interpersonal psychotherapy for perinatal depression. Arch Womens Ment Health, 2012; 15:469–480.
46.
MulcahyR, ReayRE, WilkinsonRB, et al.A randomised control trial for the effectiveness of group interpersonal psychotherapy for postnatal depression. Arch Womens Ment Health, 2010; 13:125–139.
47.
GroteNK, SwartzHA, GeibelSL, et al.A randomized controlled trial of culturally relevant, brief interpersonal psychotherapy for perinatal depression. Psychiatr Serv, 2009; 60:313–321.
48.
BurtVK, SuriR, AltshulerL, et al.The use of psychotropic medications during breast-feeding. Am J Psychiatry, 2001; 158:1001–1009.
49.
HaleT.Medications and Mothers Milk, 16th ed. Hale Publishing, Plano, TX, 2014.
50.
WeissmanAM, LevyBT, HartzAJ, et al.Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry, 2004; 161:1066–1078.
51.
MolyneauxE, HowardLM, McGeownHR, et al.Antidepressant treatment for postnatal depression. Cochrane Database Syst Rev, 2014; 9:CD002018.
52.
HeikkinenT, EkbladU, KeroP, et al.Citalopram in pregnancy and lactation. Clin Pharmacol Ther, 2002; 2:184–191.
53.
LeeA, WooJ, ItoS. Frequency of infant adverse events that are associated with citalopram use during breast-feeding. Am J Obstet Gynecol, 2004; 190:218–221.
54.
SchmidtK, OlesenOV, JensenPN. Citalopram and breast-feeding: Serum concentration and side effects in the infant. Biol Psychiatry, 2000; 47:164–165.
55.
BellantuonoC, BozziF, OrsoliniL, et al.The safety of escitalopram during pregnancy and breastfeeding: A comprehensive review. Hum Psychopharmacol, 2012; 27:534–539.
56.
BrentNB, WisnerKL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin Pediatr (Phila), 1998; 37:41–44.
57.
KristensenJH, IlettKF, HackettLP, et al.Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol, 1999; 48:521–527.
58.
EppersonCN, JatlowPI, CzarkowskiK, et al.Maternal fluoxetine treatment in the postpartum period: Effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs. Pediatrics, 2003; 112:e425.
59.
HeikkinenT, EkbladU, PaloP, LaineK. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther, 2003; 73:330–337.
60.
HendrickV, StoweZN, AltshulerLL, et al.Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psychiatry, 2001; 50:775–782.
61.
SuriR, StoweZN, HendrickV, HostetterA, et al.Estimates of nursing infant daily dose of fluoxetine through breast milk. Biol Psychiatry, 2002; 52:446–451.
62.
LesterBM, CuccaJ, AndreozziL, et al.Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Psychiatry, 1993; 32:1253–1255.
63.
ChambersCD, AndersonPO, ThomasRG, et al.Weight gain in infants whose mothers take fluoxetine. Pediatrics, 1999; 104:e61.
64.
NightingaleSL.Fluoxetine labeling revised to identify phenytoin interaction and to recommend against use in nursing mothers. JAMA, 1994; 271:106.
65.
ArnoldLM, SuckowRF, LichtensteinPK. Fluvoxamine concentrations in breast milk and in maternal and infant sera. J Clin Psychopharmacol, 2000; 20:491–493.
66.
HaggS, GranbergK, CarleborgL. Excretion of fluvoxamine into breast milk. Br J Clin Pharmacol, 2000; 49:286–288.
67.
HendrickV, FukuchiA, AltshulerL, et al.Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry, 2001; 179:163–166.
YoshidaK, SmithB, KumarRC. Fluvoxamine in breast-milk and infant development. Br J Clin Pharmacol, 1997; 44:210–211.
70.
WrightS, DawlingS, AshfordJJ. Excretion of fluvoxamine in breast milk. Br J Clin Pharmacol, 1991; 31:209.
71.
MiseryS, KimJ, RiggsKW, KostarasX. Protein levels in postpartum depressed women, breast milk, and infant serum. J Clin Psychiatry, 2000; 61:828–832.
72.
StoweZN, CohenLS, HostettlerA, et al.Paroxetine in human breast milk and nursing infants. Am J Psychiatry, 2000; 157:185–189.
73.
MerlobP, StahlB, SulkesJ. Paroxetine during breast-feeding: Infant weight gain and maternal adherence to counsel. Eur J Pediatr, 2004; 163:135–139.
74.
EppersonCN, AndersonGM, McDougleCJ. Sertraline and breast-feeding. N Engl J Med, 1997; 336:1189–1190.
75.
StoweZN, OwensMJ, LandryJC, et al.Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry, 1997; 154:1255–1260.
76.
EppersonN, CzarkowskiKA, Ward-O'BrienD, et al.Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am J Psychiatry, 2001; 158:1631–1637.
77.
WisnerKL, PerelJM, BlumerJ. Serum sertraline and N-desmethylsertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry, 1998; 155:690–692.
78.
DoddS, StockyA, BuistA, et al.Sertraline analysis in the plasma of breast-fed infants. Aust N Z J Psychiatry, 2001; 35:545–546.
79.
ItoS, KorenG. Antidepressants and breast-feeding. Am J Psychiatry, 1997; 154:1174.
80.
OlivierJD, AkerudH, KaiholaH, et al.The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring. Front Cell Neurosci, 2013; 7:73.
81.
AustinMP, KaratasJC, MishraP, et al.Infant neurodevelopment following in utero exposure to antidepressant medication. Acta Paediatr, 2013; 102:1054–1059.
82.
RamponoJ, TeohS, HackettLP, et al.Estimation of desvenlafaxine transfer into milk and infant exposure during its use in lactating women with postnatal depression. Arch Womens Ment Health, 2011; 14:49–53.
83.
IlettKF, KristensenJH, HackettLP, et al.Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol, 2002; 53:17–22.
84.
BoycePM, HackettLP, IlettKF. Duloxetine transfer across the placenta during pregnancy and into milk during lactation. Arch Womens Ment Health, 2011; 14:169–172.
85.
BaabSW, PeindlKS, PiontekCM, et al.Serum bupropion levels in two breastfeeding mother-infant pairs. J Clin Psychiatry, 2002; 63:910–911.
86.
NeumanG, ColantonioD, DelaneyS, et al.Bupropion and escitalopram during lactation. Ann Pharmacother, 2014; 48:928–931.
87.
ChaudronLH, SchoeneckerCJ. Bupropion and breastfeeding: A case of a possible infant seizure. J Clin Psychiatry, 2004; 65:881–882.
88.
DavisMF, MillerHS, NolanPEJr. Bupropion levels in breast milk for four mother-infant pairs: More answers to lingering questions. J Clin Psychiatry, 2009; 70:297–298.
89.
AichhornWMD, WhitworthABM, WeissUMD, et al.Mirtazapine and breast-feeding. Am J Psychiatry, 2004; 161:2325.
90.
WisnerKL, PerelJM. Nortriptyline treatment of breast-feeding women. Am J Psychiatry, 1996; 153:295.
91.
WisnerKL, PerelJM. Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry, 1991; 148:1234–1236.
92.
WisnerKL, PerelJM, FindlingRL, HinnesRL. Nortriptyline and its hydroxymetabolites in breastfeeding mothers and newborns. Psychopharmacol Bull, 1997; 33:249–251.
93.
FreyOR, ScheidtP, von BrenndorffAI. Adverse effects in a newborn infant breast-fed by a mother treated with doxepin. Ann Pharmacother, 1999; 33:690–693.
94.
FreemanMP, HibbelnJR, WisnerKL, et al.Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand, 2006; 113:31–35.
95.
LeeA, MinhasR, MatsudaN, et al.The safety of St. John's wort (Hypericum perforatum) during breast-feeding. J Clin Psychiatry, 2003; 64:966–968.
